Filed by Zimmer Holdings, Inc.
                           Pursuant to Rule 425 under the Securities Act of 1933

                                                Subject Company:  Centerpulse AG
                                                   (Registration No. 333-105561)

                                          Subject Company:  InCentive Capital AG
                                                   (Registration No. 333-105562)


On August 13, 2003, Zimmer Holdings, Inc. issued the following press release.


         ZIMMER ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS

(WARSAW, IN) AUGUST 13, 2003 - Zimmer Holdings, Inc. (NYSE: ZMH) announced today
that it has adjourned its special meeting of stockholders, which was reconvened
on August 13, 2003, to 11:00 a.m., Thursday, August 21, 2003, at Zimmer's global
headquarters, 345 East Main Street, Warsaw, Indiana. The purpose of the special
meeting is to vote on the issuance of shares of Zimmer common stock in
connection with Zimmer's proposed acquisitions of Centerpulse AG and InCentive
Capital AG, a significant shareholder of Centerpulse. Approval of the issuance
requires the affirmative vote of holders of a majority of the shares of Zimmer
common stock present in person or by proxy at the special meeting and entitled
to vote thereon. At the time the special meeting was adjourned, Zimmer held
proxies for approximately 140 million shares, of which approximately 137
million shares (or 98%) were in favor of the issuance.




SAFE HARBOR STATEMENT

This press release contains forward-looking statements based on current
expectations, estimates, forecasts and projections about the orthopaedics
industry, management's beliefs and assumptions made by management.
Forward-looking statements may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "anticipates," "plans,"
"estimates," "projects," "targets," "forecasts," and "seeks" or the negative of
such terms or other variations on such terms or comparable terminology. These
statements are not guarantees of future performance and involve risks,
uncertainties and assumptions that could cause actual outcomes and results to
differ materially. These risks and uncertainties include, but are not limited
to, price and product competition, rapid technological development, demographic
changes, dependence on new product development, the mix of our products and
services, supply and prices of raw materials and products, customer demand for
our products and services, our ability to successfully integrate acquired
companies, control of costs and expenses, our ability to form and implement
alliances, international growth, U.S. and foreign government regulation,
product liability and intellectual property litigation losses, reimbursement
levels from third-party payors, general industry and market conditions and
growth rates and general domestic and international economic conditions
including interest rate and currency exchange rate fluctuations. In particular,
forward-looking statements as to Zimmer's financial and business performance
following the proposed acquisitions should be qualified by the absence of the
opportunity for Zimmer to perform comprehensive due diligence on Centerpulse or
InCentive Capital AG, a significant shareholder of Centerpulse. These forward
looking statements might have been significantly different had such due
diligence review been undertaken. for a further list and description of such
risks and uncertainties, see the disclosure materials filed by Zimmer with the
U.S. Securities and Exchange Commission. Zimmer disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers of this document
are cautioned not to place undue reliance on these forward-looking statements,
since, while we believe the assumptions on which the forward-looking statements
are based are reasonable, there can be no assurance that these forward-looking
statements will prove to be accurate. This cautionary statement is applicable
to all forward-looking statements contained in this document.

This press release is neither an offer to purchase nor a solicitation of an
offer to sell any securities. any exchange offer will be made only through a
registration statement and related materials. Zimmer and its directors, officers
and other members of its management and employees also may be soliciting proxies
from Zimmer stockholders in connection with the exchange offers for shares of
Centerpulse and InCentive Capital AG. Investors and security holders should note
that the exchange offers described in this press release have not been agreed to
by Centerpulse or InCentive Capital AG and are subject to certain conditions. In
connection with the exchange offers, Zimmer has filed registration statements on
Form S-4 (each containing a prospectus/offer to purchase) and a proxy statement
on Schedule 14A with the U.S. Securities and Exchange Commission and submitted
Swiss offer prospectuses to the Swiss takeover board. Investors and security
holders of Centerpulse, InCentive Capital AG and Zimmer are advised to read
these disclosure materials (including other disclosure materials when they
become available), because these materials contain important information.
Investors and security holders may obtain a free copy of the disclosure
materials and other documents filed by Zimmer with the U.S. Securities and
Exchange Commission at the SEC'S website at www.sec.gov. The disclosure
materials and other documents of Zimmer may also be obtained from Zimmer upon
request by directing such request to Sam Leno, Senior Vice President and CFO,
574-372-4790.



ABOUT ZIMMER HOLDINGS, INC.

Zimmer, based in Warsaw, Indiana, is a worldwide leader in the design,
development, manufacture and marketing of reconstructive orthopaedic implants
and trauma products. Orthopaedic reconstruction implants restore joint function
lost due to disease or trauma in joints such as knees, hips, shoulders and
elbows. Trauma products are devices used primarily to reattach or stabilize
damaged bone and tissue to support the body's natural healing process. Zimmer
manufactures and markets other products related to orthopaedic surgery. For the
year 2002, the Company recorded worldwide revenues of $1.37 billion. Zimmer was
founded in 1927 and has more than 3,600 employees worldwide.

                                      # # #

Additional contacts:

         Switzerland:     Hirzel. Neef. Schmid. Konsulenten
                          Aloys Hirzel/+41 43 344 42 49/a-hirzel@konsulenten.ch
                          Andreas Thommen/+41 43 344 42 49/
                          a-thommen@konsulenten.ch

         U.K.:   M Communications
                 Hugh Morrison/+44 207 153 1534/morrison@mcomgroup.com
                 Nick Miles/+44 207 153 1535/miles@mcomgroup.com